HALOZYME THERAPEUTICS, INC.

Licenses a drug delivery platform to biopharma, converting IV drugs to subcutaneous injections.

HALO | NDAQ

Overview

Corporate Details

ISIN(s):: US40637H1095
LEI:
Country:: United States of America
Address:: 12390 EL CAMINO REAL, 92130 SAN DIEGO
Website:: https://www.halozyme.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Halozyme Therapeutics, Inc. is a biotechnology company focused on its proprietary drug delivery technology platform, ENHANZE®. This technology facilitates the subcutaneous (under-the-skin) delivery of injectable drugs and biologics that are often administered intravenously. Halozyme licenses its ENHANZE® technology to global biopharmaceutical companies, enabling them to develop new formulations of their therapies. This model aims to reinvent the patient experience by reducing treatment burden and shortening administration times, particularly in therapeutic areas such as oncology. The company's commercial portfolio is primarily built on royalties and milestone payments derived from its partners' sales of products utilizing the ENHANZE® platform.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all HALOZYME THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HALOZYME THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for HALOZYME THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Xplus Inc. IT consultancy guiding digital transformation via enterprise architecture & program management.	South Korea	373200
XTL Biopharmaceuticals Ltd. Acquires and develops late-stage drugs for unmet medical needs, focusing on autoimmune diseases.	Israel	XTLB
XTL BIOPHARMACEUTICALS LTD Acquires and develops late-stage drug candidates for treating autoimmune diseases.	United States of America	XTLB
YAMADA Consulting Group CO.,LTD. Japanese consulting firm offering global M&A, strategy, and financial advisory services.	Japan	4792
Y-Biologics, Inc Develops novel antibody cancer therapies using proprietary T-cell engager & antibody library tech.	South Korea	338840
Yellow Balloon Tour Co., Ltd. Offers domestic & international travel packages, flights, and tours for individuals and groups.	South Korea	104620
Yoshimura Food Holdings K.K. Acquires and revitalizes Japanese food SMEs via a support platform for global expansion.	Japan	2884
Ziccum AB Licenses ambient drying tech for pharma to create stable, cold-chain-free biologics.	Sweden	ZICC
グロービング株式会社 Accelerates business growth via strategic consulting, AI implementation, and proprietary SaaS.	Japan	277A
株式会社Ｄ＆Ｍカンパニー Optimizing healthcare & welfare businesses via finance, consulting, and HR solutions.	Japan	189A